Le Lézard
Classified in: Health, Business
Subject: PDT

The Assistance Fund Opens New Program for Mucopolysaccharidosis Type 1 - MPS Disease


ORLANDO, Fla., Jan. 21, 2020 /PRNewswire/ -- The Assistance Fund (TAF), an independent, charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today announced the launch of a new financial assistance program for people living with mucopolysaccharidosis type 1 (MPS 1). The program is designed to help eligible individuals pay for their out-of-pocket medical expenses resulting from the condition.

MPS 1 is a rare lysosomal disease affecting multiple parts of the body. The lack of a specific enzyme leads to a growth of glycosaminoglycans and growth in the size in lysosomes, causing an enlargement in tissues and organs. MPS 1 includes Hurler syndrome, Scheie syndrome and Hurler-Scheie syndrome, each differing in their severity. MPS 1 typically begins six months after birth, affecting one out of every 500,000 newborns.[1]

"While the search for a cure continues, TAF's new Mucopolysaccharidosis Type 1 Financial Assistance Program aims to eliminate the burden of out-of-pocket costs for families dealing with an MPS 1 diagnosis so they can focus on managing their treatment," said Mark McGreevy, President and CEO of The Assistance Fund.

"Individuals with MPS 1 face a lifetime of medical interventions to improve their quality of life and slow the progression of the disease," said Terri Klein, President and CEO at the National MPS Society. "Treatment is vital to help prevent irreversible organ and tissue damage, but the high costs associated with care can make it out of reach for many families. With support from The Assistance Fund, more patients with MPS 1 will undergo the treatment regimens that can best preserve their health. We are grateful for organizations like the Assistance Fund who are willing to help with the heavy financial burden felt by our patients."

To learn more or determine eligibility for financial support, visit tafcares.org or call (855) 267-2054 to speak with a Patient Advocate.

A list of all the programs available from The Assistance Fund is available at tafcares.org.

About The Assistance Fund

The Assistance Fund is an independent, charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs by providing financial assistance for their copayments, coinsurance, deductibles and other health-related expenses. The Assistance Fund currently manages more than 60 programs ? each of which covers the FDA-approved medications that treat a specific disease. Since its founding in 2009, The Assistance Fund has helped more than 78,000 adults and children access the medicines they need to stay healthy or manage a chronic condition. To learn more about The Assistance Fund, or for information on how to donate, please visit tafcares.org.

Media Contact

Margaret Figley

Director of Communications

[email protected]

 

[1] "MPS I (Hurler, Hurler-Scheie, Scheie syndrome)." The National MPS Society. (November 14, 2019) Retrieved from: https://mpssociety.org/learn/diseases/mps-i/

SOURCE The Assistance Fund


These press releases may also interest you

at 23:00
GenScript, a global leader in life sciences and biotechnology, successfully hosted an Open Day event at its Singapore facility on the 16th of April, welcoming more than 50 representatives from Singapore. This event provided an exclusive look into...

at 23:00
Cybervation, an award-winning global technology and healthcare solutions company, proudly announces that its CEO, Purba Majumder, has been distinguished as one of the 2024 100 Women to KNOW Across America. This award from KNOW Women recognizes...

at 22:33
The report titled "Glycated Albumin Assay Market by Product (Animal Glycated Albumin Assay, Human Glycated Albumin Assay), Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User - Global Forecast 2024-2030" is now available on...

at 22:03
The report titled "Health & Wellness Food Market by Type (Fresh & Natural, Functional Foods & Beverages, Heat & Eat), Nature (Genetically Modified Organism Food, Non-Genetically Modified Organism Food), Fat Content, Category, Free From Category,...

at 21:27
Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and...

at 19:30
Astellas Pharma Inc....



News published on and distributed by: